background pattern

Creating novel therapeutics
for patients with excellent expertise
in kinase inhibitors

 
PIPELINE

A precisely crafted pipeline, accelerating the pace of drug discovery.

With hundreds of thousands of experimental data points and robust target validation, Voronoi rapidly identifies and optimizes promising drug candidates. Discover how innovation unfolds in our pipeline.

 
Publications

Science with purpose.

From design to clinic delivering targeted therapies that matter. Explore our research and breakthroughs.

background pattern
OUR Approach

VORONOMICS-Based Drug Design

VORONOMICS, a proprietary platform, revolutionizes the drug development process, enabling the rapid discovery of development candidates with exquisite selectivity and brain penetration that are unprecedent.

Careers

Science moves faster when we move together.
we turn collaboration into discovery.

bg-our-mission-left bg-our-mission-right
Voronoi Team
Voronoi Team
Voronoi Team
Voronoi Team
Voronoi Team

Work and enjoyment come together naturally

with spontaneous connections that make collaboration flow, in a space full of energy, ideas, and deep focus.
We experience both concentration and genuine joy, from sleek,
comfortable labs that foster scientific immersion to casual ping-pong matches and quick energy boosts at the snack corner at Voronoi.

Join our team

Latest Highlights

ASCO Annual Meeting 2026

Voronoi is excited to participate in the ASCO annual meeting 2026

  • calendar icon Date & Time: May 29 - June 2, 2026
  • location icon Location: McCormick Place, Chicago, IL

Latest News

  • 2026.08.18
보로노이, 차세대 폐암 표적 치료제 VRN11 싱가포르 IND 승인…EGFR 폐암 1차 치료 글로벌 임상 확대

보로노이(310210)는 차세대 EGFR 비소세포폐암 표적치료제 ‘VRN11’의 글로벌 1b/2상 임상시험계획(IND)을 싱가포르 보건과학청(HSA)으로부터 승인받았다고 18일 공시했다.

  • 2026.08.07
보로노이, VRN11 캐나다 IND 제출…북미 임상 개발 본격화

보로노이(310210)는 차세대 EGFR 표적치료제 VRN11의 글로벌 1b/2상 임상시험을 위해 캐나다 보건부에 임상시험계획(IND)을 제출했다고 7일 밝혔다.